Myeloma and AL amyloidosis ASH 2024 previewAccess, AL amyloidosis, CAR-T, MPE, MyelomaNovember 29, 2024
MPE encourages EMA to review its negative recommendation for ixazomibAccess, MPE, MyelomaAugust 16, 2016
EMA reconsiders and gives its positive opinion for the approval of ixazomibAccess, MyelomaSeptember 17, 2016
Delays in access to new cancer medicines and unjustifiable price rises for old ones disadvantage patients unnecessarilyAccessJanuary 28, 2017
Myeloma Patients Europe (MPE) relaunches Myeloma Access Atlas platformAccess, MPE, MyelomaOctober 19, 2021
Takeda announces discontinuation of the phase 3 clinical trial TOURMALINE-AL1 in AL amyloidosisAccess, AL amyloidosisJune 6, 2019
The European Medicines Agency (EMA) approves Melflufen (Pepaxti®) for the treatment of refractory myelomaAccess, MyelomaAugust 30, 2022
EMA CHMP gives positive opinion on isatuximab combination for newly diagnosed myeloma patientsAccess, latest, Myeloma, NewsNovember 20, 2024
MPE comments on the Implementing Regulation on joint scientific consultations on medicinal products for human use at Union levelAccess, latest, NewsOctober 29, 2024
The FDA approves belantamab mafodotin for relapsed or refractory myelomaAccess, MyelomaAugust 6, 2020
